Position in EXEL
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$1,104,087
+$559,213 QoQ
Shares Held
20,292
+59.7% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#32
of 112 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sequoia Financial Advisors, LLC holds $32,926,453 across 49 Biotechnology names. EXEL ranks #7 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,729 | $8,309,796 | |
| 2 | FTRE |
Fortrea Holdings Inc.
|
175,864 | $3,060,033 | |
| 3 | INCY |
Incyte Corp
|
19,250 | $2,182,180 | |
| 4 | ARGX |
Argenx SE
|
2,045 | $1,897,289 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,687 | $1,675,451 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
4,347 | $1,308,577 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
20,292 | $1,104,087 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
4,527 | $1,090,871 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,104,087 | 20,292 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $544,874 | 12,704 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $760,669 | 17,355 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $304,835 | 7,381 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $299,964 | 6,805 | Shares | Sole | 2025-07-25 | |
| No filing history on record for this holder in this stock. | ||||||